Loading
Ursula Matulonis led the MIRASOL trial that gave ovarian cancer its first ADC with a survival benefit.
Ursula A. Matulonis is Chief of the Division of Gynecologic Oncology at Dana-Farber Brigham Cancer Center. She is a gynaecologic oncologist known for leading the MIRASOL trial of mirvetuximab soravtansine, which gave ovarian cancer its first antibody-drug conjugate, as well as trials of PARP inhibitors and bevacizumab combinations. Her selected paper reports mirvetuximab soravtansine in folate receptor alpha-positive, platinum-resistant ovarian cancer. She continues to lead trials of PARP inhibitors such as olaparib and of ADCs in ovarian cancer.
| Title | Journal | Year |
|---|---|---|
| Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer | New England Journal of Medicine | 2023 |
Shares MIRASOL / GOG-3045, Folate receptor alpha, Mirvetuximab soravtansine, PARP.
Shares Folate receptor alpha, Mirvetuximab soravtansine, PARP, Olaparib.
Shares Folate receptor alpha, Mirvetuximab soravtansine, Ovarian cancer.
Shares PARP, Olaparib, Ovarian cancer.
Shares Mirvetuximab soravtansine, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/